Neuropathic Back Pain – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of neuropathic back pain (NBP) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of NBP for each country, as well as annualized case counts projected to the national population. Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
Clarivate Epidemiology’s NBP forecast will answer the following question:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of NBP over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology forecasts three NBP patient populations, as follows:
- Total prevalent cases of NBP.
- Diagnosed prevalent cases of NBP.
- Diagnosed drug-treated prevalent cases of NBP.
Note: Coverage may vary by country.
Table of contents
- Neuropathic Back Pain - Epidemiology - Mature Markets
- Epidemiology Data
- Methods
- Literature review (studies included in/excluded from the analyses of neuropathic back pain)
- Total prevalent cases of neuropathic back pain
- Diagnosed prevalent cases of neuropathic back pain
- Diagnosed drug-treated prevalent cases of neuropathic back pain
- Risk / protective factors applied to disease forecast models
- Reference Materials
